181 related articles for article (PubMed ID: 36509998)
1. Targeting PEA3 transcription factors to mitigate small cell lung cancer progression.
Shia DW; Choi W; Vijayaraj P; Vuong V; Sandlin JM; Lu MM; Aziz A; Marin C; Aros CJ; Sen C; Durra A; Lund AJ; Purkayastha A; Rickabaugh TM; Graeber TG; Gomperts BN
Oncogene; 2023 Feb; 42(6):434-448. PubMed ID: 36509998
[TBL] [Abstract][Full Text] [Related]
2. MCAM Mediates Chemoresistance in Small-Cell Lung Cancer via the PI3K/AKT/SOX2 Signaling Pathway.
Tripathi SC; Fahrmann JF; Celiktas M; Aguilar M; Marini KD; Jolly MK; Katayama H; Wang H; Murage EN; Dennison JB; Watkins DN; Levine H; Ostrin EJ; Taguchi A; Hanash SM
Cancer Res; 2017 Aug; 77(16):4414-4425. PubMed ID: 28646020
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of p62/SQSTM1 sensitizes small-cell lung cancer cells to cisplatin-induced cytotoxicity by targeting NEDD9 expression.
Xu L; Xu F; Kong Q; Yang T; Tan D; Zhang X; Li N; Zhao S; Zhao J; Li M
Mol Carcinog; 2020 Aug; 59(8):967-979. PubMed ID: 32424979
[TBL] [Abstract][Full Text] [Related]
4. Activation of the PI3K/mTOR Pathway following PARP Inhibition in Small Cell Lung Cancer.
Cardnell RJ; Feng Y; Mukherjee S; Diao L; Tong P; Stewart CA; Masrorpour F; Fan Y; Nilsson M; Shen Y; Heymach JV; Wang J; Byers LA
PLoS One; 2016; 11(4):e0152584. PubMed ID: 27055253
[TBL] [Abstract][Full Text] [Related]
5. MYC drives platinum resistant SCLC that is overcome by the dual PI3K-HDAC inhibitor fimepinostat.
Chen J; Guanizo AC; Jakasekara WSN; Inampudi C; Luong Q; Garama DJ; Alamgeer M; Thakur N; DeVeer M; Ganju V; Watkins DN; Cain JE; Gough DJ
J Exp Clin Cancer Res; 2023 Apr; 42(1):100. PubMed ID: 37098540
[TBL] [Abstract][Full Text] [Related]
6. EPHA3 regulates the multidrug resistance of small cell lung cancer via the PI3K/BMX/STAT3 signaling pathway.
Peng J; Wang Q; Liu H; Ye M; Wu X; Guo L
Tumour Biol; 2016 Sep; 37(9):11959-11971. PubMed ID: 27101199
[TBL] [Abstract][Full Text] [Related]
7. Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1.
Byers LA; Wang J; Nilsson MB; Fujimoto J; Saintigny P; Yordy J; Giri U; Peyton M; Fan YH; Diao L; Masrorpour F; Shen L; Liu W; Duchemann B; Tumula P; Bhardwaj V; Welsh J; Weber S; Glisson BS; Kalhor N; Wistuba II; Girard L; Lippman SM; Mills GB; Coombes KR; Weinstein JN; Minna JD; Heymach JV
Cancer Discov; 2012 Sep; 2(9):798-811. PubMed ID: 22961666
[TBL] [Abstract][Full Text] [Related]
8. Activation of PI3K/AKT Pathway Is a Potential Mechanism of Treatment Resistance in Small Cell Lung Cancer.
Jin Y; Chen Y; Tang H; Hu X; Hubert SM; Li Q; Su D; Xu H; Fan Y; Yu X; Chen Q; Liu J; Hong W; Xu Y; Deng H; Zhu D; Li P; Gong Y; Xia X; Gay CM; Zhang J; Chen M
Clin Cancer Res; 2022 Feb; 28(3):526-539. PubMed ID: 34921019
[TBL] [Abstract][Full Text] [Related]
9. Two novel determinants of etoposide resistance in small cell lung cancer.
Lawson MH; Cummings NM; Rassl DM; Russell R; Brenton JD; Rintoul RC; Murphy G
Cancer Res; 2011 Jul; 71(14):4877-87. PubMed ID: 21642373
[TBL] [Abstract][Full Text] [Related]
10. Targeting a non-oncogene addiction to the ATR/CHK1 axis for the treatment of small cell lung cancer.
Doerr F; George J; Schmitt A; Beleggia F; Rehkämper T; Hermann S; Walter V; Weber JP; Thomas RK; Wittersheim M; Büttner R; Persigehl T; Reinhardt HC
Sci Rep; 2017 Nov; 7(1):15511. PubMed ID: 29138515
[TBL] [Abstract][Full Text] [Related]
11. FGFRL1 affects chemoresistance of small-cell lung cancer by modulating the PI3K/Akt pathway via ENO1.
Chen R; Li D; Zheng M; Chen B; Wei T; Wang Y; Li M; Huang W; Tong Q; Wang Q; Zhu Y; Fang W; Guo L; Fang S
J Cell Mol Med; 2020 Feb; 24(3):2123-2134. PubMed ID: 31957179
[TBL] [Abstract][Full Text] [Related]
12. ESRP1 regulates alternative splicing of CARM1 to sensitize small cell lung cancer cells to chemotherapy by inhibiting TGF-β/Smad signaling.
Zheng M; Niu Y; Bu J; Liang S; Zhang Z; Liu J; Guo L; Zhang Z; Wang Q
Aging (Albany NY); 2021 Jan; 13(3):3554-3572. PubMed ID: 33495408
[TBL] [Abstract][Full Text] [Related]
13. Intensified Beclin-1 Mediated by Low Expression of Mir-30a-5p Promotes Chemoresistance in Human Small Cell Lung Cancer.
Yang X; Bai F; Xu Y; Chen Y; Chen L
Cell Physiol Biochem; 2017; 43(3):1126-1139. PubMed ID: 28977798
[TBL] [Abstract][Full Text] [Related]
14. YAP1 promotes multidrug resistance of small cell lung cancer by CD74-related signaling pathways.
Song Y; Sun Y; Lei Y; Yang K; Tang R
Cancer Med; 2020 Jan; 9(1):259-268. PubMed ID: 31692299
[TBL] [Abstract][Full Text] [Related]
15.
Li M; Lin A; Luo P; Shen W; Xiao D; Gou L; Zhang J; Guo L
Aging (Albany NY); 2020 Jan; 12(2):1285-1303. PubMed ID: 31959735
[TBL] [Abstract][Full Text] [Related]
16. Combination of arsenic trioxide and chemotherapy in small cell lung cancer.
Zheng CY; Lam SK; Li YY; Fong BM; Mak JC; Ho JC
Lung Cancer; 2013 Nov; 82(2):222-30. PubMed ID: 24041618
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of Karyopherin β1-Mediated Nuclear Import Disrupts Oncogenic Lineage-Defining Transcription Factor Activity in Small Cell Lung Cancer.
Kelenis DP; Rodarte KE; Kollipara RK; Pozo K; Choudhuri SP; Spainhower KB; Wait SJ; Stastny V; Oliver TG; Johnson JE
Cancer Res; 2022 Sep; 82(17):3058-3073. PubMed ID: 35748745
[TBL] [Abstract][Full Text] [Related]
18. NK Cells Mediate Synergistic Antitumor Effects of Combined Inhibition of HDAC6 and BET in a SCLC Preclinical Model.
Liu Y; Li Y; Liu S; Adeegbe DO; Christensen CL; Quinn MM; Dries R; Han S; Buczkowski K; Wang X; Chen T; Gao P; Zhang H; Li F; Hammerman PS; Bradner JE; Quayle SN; Wong KK
Cancer Res; 2018 Jul; 78(13):3709-3717. PubMed ID: 29760044
[TBL] [Abstract][Full Text] [Related]
19. Poly (ADP) ribose polymerase enzyme inhibitor, veliparib, potentiates chemotherapy and radiation in vitro and in vivo in small cell lung cancer.
Owonikoko TK; Zhang G; Deng X; Rossi MR; Switchenko JM; Doho GH; Chen Z; Kim S; Strychor S; Christner SM; Beumer J; Li C; Yue P; Chen A; Sica GL; Ramalingam SS; Kowalski J; Khuri FR; Sun SY
Cancer Med; 2014 Dec; 3(6):1579-94. PubMed ID: 25124282
[TBL] [Abstract][Full Text] [Related]
20. Unexpected favorable outcome to etoposide and cisplatin in a small cell lung cancer transformed patient: a case report.
Xie Z; Gu Y; Lin X; Ouyang M; Qin Y; Zhang J; Liu J; Mai S; Zhou C
Cancer Biol Ther; 2019; 20(9):1172-1175. PubMed ID: 31161851
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]